Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole IV-to-oral pharmacokinetics in immunocompromised children at high risk for systemic fungal infection
jRCT2080221537Phase 2
- Sponsor
- Pfizer
- Start
- Aug 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of voriconazole in invasive mycoses (2 arms), sponsored by Pfizer. Primary endpoints: Pharmacokinetics of voriconazole and Safety and tolerability of voriconazole.
02
Drugs
voriconazole
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on jRCT2080221537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221537.